Wayne P Gulliver1, Kenneth A Baker. 1. Faculty of Medicine, Memorial University of Newfoundland, Newlab Scinces Incorporated, St. John's NL. wgulliver@newlabresearch.com
Abstract
BACKGROUND: Moderate to severe chronic hand dermatitis (CHD) is not well controlled by current medical strategies; however, recent studies have shown significant improvement in patients treated with up to 6 months of oral alitretinoin (9-cis-retinoic acid). The results of longer-term continuous treatment are lacking. OBJECTIVE: To evaluate the long-term safety and efficacy of alitretinoin for the treatment of CHD. METHODS: The Physician's Global Assessment (PGA) and Modified Total Lesion Symptom Score (MTLSS) were used to assess CHD improvement in three patients treated with alitretinoin (10-30 mg/d). Patients had routine bloodwork and were monitored for adverse events. RESULTS: Significant improvement in MTLSS scores (≈ 76%) was seen at 2 months (p < .002) and maintained for the 3-year treatment period with occasional dosage adjustments. No significant adverse events developed that necessitated treatment withdrawal. CONCLUSION: Alitretinoin was well tolerated in the treatment of these three CHD patients who were carefully monitored over this prolonged treatment period.
BACKGROUND: Moderate to severe chronic hand dermatitis (CHD) is not well controlled by current medical strategies; however, recent studies have shown significant improvement in patients treated with up to 6 months of oral alitretinoin (9-cis-retinoic acid). The results of longer-term continuous treatment are lacking. OBJECTIVE: To evaluate the long-term safety and efficacy of alitretinoin for the treatment of CHD. METHODS: The Physician's Global Assessment (PGA) and Modified Total Lesion Symptom Score (MTLSS) were used to assess CHD improvement in three patients treated with alitretinoin (10-30 mg/d). Patients had routine bloodwork and were monitored for adverse events. RESULTS: Significant improvement in MTLSS scores (≈ 76%) was seen at 2 months (p < .002) and maintained for the 3-year treatment period with occasional dosage adjustments. No significant adverse events developed that necessitated treatment withdrawal. CONCLUSION:Alitretinoin was well tolerated in the treatment of these three CHD patients who were carefully monitored over this prolonged treatment period.
Authors: Jung Eun Seol; Jong Uk Kim; Seong Min Hong; Gyeong Je Cho; Woo Jung Jin; So Hee Park; In Ho Park; So Young Jung; Hyojin Kim Journal: Ann Dermatol Date: 2020-12-30 Impact factor: 1.444